PharmaShots | Incisive News in 3 Shots

Subscribe Now

BridgeBio

BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type A

BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type...

August 12, 2022

BridgeBio Reports Results of BBP-812 in the P-I/II (CANaspire) Trial for the Treatment of Canavan Disease

BridgeBio Reports Results of BBP-812 in the P-I/II (CANaspire) Trial for the Treatment of Canavan Disease

June 23, 2022

Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer

Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer

May 13, 2022

BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor Deficiency

BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor De...

March 9, 2022

BridgeBio Reports First Patient Dosing in P-I/II (ADventure) Trial for the Treatment of Congenital Adrenal Hyperplasia

BridgeBio Reports First Patient Dosing in P-I/II (ADventure) Trial for the Treatment of Congenital Adrenal Hyperplasia

January 28, 2022

BridgeBio and Amgen Entered into a Non-Exclusive Clinical Collaboration for BBP-398 in P-I/II Study for Advanced Solid Tumors

BridgeBio and Amgen Entered into a Non-Exclusive Clinical Collaboration for BBP-398 in P-I/II Study for Advanced Solid Tumors

January 14, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us